Invivyd Stock (NASDAQ:IVVD)


ForecastOwnershipFinancialsChartTranscripts

Previous Close

$0.55

52W Range

$0.35 - $2.81

50D Avg

$1.01

200D Avg

$0.90

Market Cap

$62.99M

Avg Vol (3M)

$15.16M

Beta

0.41

Div Yield

-

IVVD Company Profile


Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

99

IPO Date

Aug 06, 2021

Website

IVVD Performance


IVVD Financial Summary


Dec 24Dec 23Dec 22
Revenue$25.38M--
Operating Income$-176.88M$-207.78M$-248.03M
Net Income$-169.93M$-198.64M$-234.60M
EBITDA$-176.88M$-196.62M$-248.03M
Basic EPS$-1.43$-1.81$-2.17
Diluted EPS$-1.43$-1.81$-2.17

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 14, 24 | 9:14 AM
Q2 24Aug 14, 24 | 8:30 AM
Q1 24May 09, 24 | 4:30 PM

Peer Comparison


TickerCompany
RGNXREGENXBIO Inc.
CCCCC4 Therapeutics, Inc.
KRONKronos Bio, Inc.
RXRXRecursion Pharmaceuticals, Inc.
BDTXBlack Diamond Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
APVOAptevo Therapeutics Inc.
AVIRAtea Pharmaceuticals, Inc.
PASGPassage Bio, Inc.
ERASErasca, Inc.
UBXUnity Biotechnology, Inc.
EWTXEdgewise Therapeutics, Inc.
ABEOAbeona Therapeutics Inc.
GBIOGeneration Bio Co.